# US 2016/0251444 A1 · Therapeutic use of anti-cd22 antibodies for inducing trogocytosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251444 A1
- Document ID: US20160251444A1
- Status: Published application
- Kind: A1
- Application number: 15/157,986
- Filed: 2016-05-18
- Published: 2016-09-01
- Earliest claimed: 2011-12-05
- Assignees: Immunomedics, Inc.
- Applicants: Immunomedics, Inc.
- Inventors: Chien-Hsing Chang; David M. Goldenberg; Hans J. Hansen; Edmund A. Rossi
- Web page: https://patentgrep.com/patent/US20160251444A1

## CPC

- C07K 16/2887: {against CD20}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/56: IFN-alpha
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of B-cell antigens, such as CD19, CD20, CD21, CD22, CD79b, CD44, CD62L, or β7-integrin. Trogocytosis may play a significant role in determining antibody efficacy, disease responsiveness and prognosis of therapeutic intervention and trogocytosis-dependent responses may be monitored by measuring the levels of trogocytosis of one or more B-cell surface antigens induced by the bispecific antibody.

## Claims

### Claim 1

A method of treating systemic lupus erythematosus (SLE) comprising administering to a human subject with SLE a bispecific anti-CD22×anti-CD20 antibody comprising (i) a first antibody, wherein the C-terminal end of each light chain of the first antibody is conjugated to an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP); and (ii) an antigen-binding fragment of a second antibody, conjugated to a dimerization and docking domain (DDD) moiety from human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form a complex; wherein the antibody induces trogocytosis of one or more B-cell surface antigens selected from the group consisting of CD19, CD20, CD21, CD22, CD79b, CD44, CD62L and β7-integrin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody induces trogocytosis of one or more B-cell surface antigens when exposed to B cells in vitro in the presence of PBMCs or purified FcγR-positive cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody induces trogocytosis of one or more B-cell surface antigens when exposed to circulating B cells in vivo.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is a chimeric, humanized, or human antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody induces trogocytosis of one or more B-cell antigens, without depleting circulating B cells by more than 50%, when the antibody is administered to a subject.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering a therapeutic agent to the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein the therapeutic agent is selected from the group consisting of a drug, prodrug, immunomodulator, cytokine, chemokine, pro-apoptotic agent, anti-angiogenic agent, tyrosine kinase inhibitor, Bruton kinase inhibitor, sphingosine inhibitor, enzyme, hormone, photoactive agent, siRNA and RNAi.

### Claim 8 (depends on 7)

The method of claim 7, wherein the drug is selected from the group consisting of 5-fluorouracil, aplidin, azaribine, anastrozole, anthracyclines, bendamustine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatinum, Cox-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicine (2PDOX), pro-2PDOX, cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, estramustine, epipodophyllotoxin, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, gemcitabine, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, lenolidamide, leucovorin, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, nitrosourea, plicomycin, procarbazine, paclitaxel, pentostatin, PSI-341, raloxifene, semustine, streptozocin, tamoxifen, temazolomide (an aqueous form of DTIC), transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinorelbine, vinblastine, vincristine and vinca alkaloids.

### Claim 9 (depends on 7)

The method of claim 7, wherein the tyrosine kinase inhibitor is selected from the group consisting of canertinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, leflunomide, nilotinib, pazopanib, semaxinib, sorafenib, sunitinib, sutent and vatalanib.

### Claim 10 (depends on 7)

The method of claim 7, wherein the Bruton kinase inhibitor is selected from the group consisting of PCI-32765 (ibrutinib), PCI-45292, GDC-0834, LFM-A13 and RN486.

### Claim 11 (depends on 7)

The method of claim 7, wherein the immunomodulator is selected from the group consisting of a cytokine, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor, erythropoietin, thrombopoietin, tumor necrosis factor-α (TNF-α), TNF-β, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-α, interferon-β, interferon-λ, interferon-γ, “S1 factor”, human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, NGF-β, platelet-growth factor, TGF-α, TGF-β, insulin-like growth factor-I, insulin-like growth factor-II, M-CSF, interleukin-1 (IL-1), IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-23, IL-25, LIF, kit-ligand (FLT-3), angiostatin, thrombospondin, endostatin, and lymphotoxin.

### Claim 12 (depends on 7)

The method of claim 7, wherein the anti-angiogenic agent is selected from the group consisting of angiostatin, baculostatin, canstatin, maspin, anti-placenta growth factor (anti-P1GF), anti-VEGF, anti-Flk-1 antibody, anti-Flt-1 antibody, anti-Kras antibody, anti-cMET antibody, anti-MIF (macrophage migration-inhibitory factor) antibody, laminin peptide, fibronectin peptide, plasminogen activator inhibitor, tissue metalloproteinase inhibitor, an interleukin-12, IP-10, Gro-β, thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, CM101, Marimastat, pentosan polysulphate, angiopoietin-2, interferon-alpha, interferon-lambda, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, angiostatin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 and minocycline.

### Claim 13 (depends on 1)

The method of claim 1, wherein the first antibody is an IgG antibody and the antigen-binding fragment of a second antibody is a Fab fragment.

### Claim 14 (depends on 13)

The method of claim 13, wherein the bispecific antibody comprises four Fab fragments of a second antibody.

### Claim 15 (depends on 13)

The method of claim 13, wherein the first or second antibody is rituximab or veltuzumab.

### Claim 16 (depends on 13)

The method of claim 13, wherein the first or second antibody is epratuzumab.

### Claim 17 (depends on 13)

The method of claim 13, wherein the IgG antibody and the antigen-binding antibody fragment are fusion proteins.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antigen-binding fragment of a second antibody is selected from the group consisting of F(ab′)2, F(ab)2, Fab′, Fab, Fv, scFv and single domain antibody fragments.
